Results 51 to 60 of about 8,636 (197)

Bevacizumab-induced atypical hemolytic uremic syndrome and treatment with eculizumab [PDF]

open access: yes, 2018
Bevacizumab (Avastin) is a recombinant humanized monoclonal antibody used for the management of various solid malignancies including colorectal, lung, brain, renal, and ovarian cancers as well as age-related macular degeneration of the eye.
Daulath Singh   +4 more
core   +1 more source

Acute ST-Segment Elevation Myocardial Infarction as Initial Presentation of Atypical Hemolytic-Uremic Syndrome

open access: yesJACC: Case Reports, 2021
A young woman presented with an acute ST-segment elevation myocardial infarction. Her clinical course was complicated by cardiogenic shock and acute renal failure. Work-up revealed thrombocytopenia and hemolytic anemia.
Edward Chau, MD, MS   +8 more
doaj   +1 more source

Hemolytic Uremic Syndrome in Pregnancy and Postpartum [PDF]

open access: yes, 2017
BACKGROUND: Pregnancy is associated with various forms of thrombotic microangiopathy, including hemolytic uremic syndrome. A previous small French study suggested that pregnancy-associated hemolytic uremic syndrome was to be included in the spectrum of ...
Remuzzi, G.   +25 more
core   +1 more source

Perinatal outcomes in normotensive versus hypertensive HELLP syndrome

open access: yesInternational Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective To compare maternal and neonatal outcomes between women with hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome with and without associated hypertension. Methods This was a retrospective cohort study at a tertiary university‐affiliated medical center including all singleton HELLP cases >24 weeks gestation (January ...
Matan Anteby   +4 more
wiley   +1 more source

How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome [PDF]

open access: yes, 2014
Thrombotic thrombocytopenic purpura (TTP) and atypical haemolytic uraemic syndrome (aHUS) are acute, rare life-threatening thrombotic microangiopathies that require rapid diagnosis and treatment.
Goodship, T, Scully, M
core  

Rare Presentation of Atypical Hemolytic Uremic Syndrome in an Adult [PDF]

open access: yes, 2021
Thrombotic microangiopathies (TMA) are disorders characterized by microangiopathic hemolytic anemia, thrombocytopenia, and microthrombi leading to organ dysfunction.
Cook, Christopher   +3 more
core   +1 more source

Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation [PDF]

open access: yes, 2016
International audienceBACKGROUND AND OBJECTIVES: The complement inhibitor eculizumab has dramatically improved the outcome of atypical hemolytic uremic syndrome.
Delmas, Yahsou   +50 more
core   +1 more source

Inborn errors of immunity in children with neuroinflammation

open access: yesDevelopmental Medicine &Child Neurology, EarlyView.
Abstract Inborn errors of immunity (IEIs), an expanding group of monogenic disorders with diverse clinical manifestations, are increasingly recognized to include neuroinflammatory disease. Examples of diseases included under this umbrella are Aicardi–Goutières syndrome, deficiency of adenosine deaminase 2, familial haemophagocytic lymphohistiocytosis ...
Eppie M Yiu   +5 more
wiley   +1 more source

Critical Appraisal Of Eculizumab For Atypical Hemolytic Uremic Syndrome [PDF]

open access: yes, 2017
The biology of atypical hemolytic uremic syndrome has been shown to involve inability to limit activation of the alternative complement pathway, with subsequent damage to systemic endothelial beds and the vasculature, resulting in the prototypic findings
Palma   +2 more
core   +1 more source

Comparative 3‐Year Allograft Outcomes for Recipients of Kidneys From SARS‐CoV‐2 NAT‐Positive Donors

open access: yesTransplant Infectious Disease, EarlyView.
In this retrospective single‐center study of 220 kidney transplants from SARS‐CoV‐2 NAT+, NAT+ with COVID as cause of death (CoV‐COD) and NATneg donors, we found no significant difference in rejection or kidney pathologies at 1 year, and death, graft loss, or eGFR at 3 years by CoV‐donor status.
Christine E. Koval   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy